63 E ect of flow on longitudinal tau PET REFERENCES 1. Jie CV, Treyer V, Schibli R, Mu L. TauvidTM: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer’s disease. Pharmaceuticals (Basel). 2021;14:110. 2. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–468. 3. Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies: still a challenge. Mol Psychiatry. 2019;24:1112–1134. 4. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–119. 5. Xia CF, Arteaga J, Chen G, et al. [18F] T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–676. 6. van Berckel BN, Ossenkoppele R, Tolboom N, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J NuclMed. 2013;54:1570–1576. 7. Ossenkoppele R, Prins ND, Van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36. 8. Golla SS, Wolters EE, Timmers T, et al. Parametric methods for [18F] flortaucipir PET. J Cereb Blood Flow Metab. 2020;40:365–373. 9. Tuncel H, Visser D, Yaqub M, et al. Effect of shortening the scan duration on quantitative accuracy of [18F] flortaucipir studies. Mol Imaging Biol. 2021;23:604–613. 10. Heeman F, Yaqub M, Lopes Alves I, et al. Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. EJNMMI Res. 2019;9:32. 11. Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A. Comparability of [18F] THK5317 and [11C] PIB blood flow proxy images with [18F] FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2017;37:740–749. 12. Peretti DE, Garcia DV, Reesink FE, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI Res. 2019;9:59. 13. Chen YJ, Rosario BL, Mowrey W, et al. Relative 11C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-PiB PET. J NuclMed. 2015;56:1199–1205. 14. Visser D, Wolters EE, Verfaillie SC, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47:3165–3175. 15. Ottoy J, Verhaeghe J, Niemantsverdriet E, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: validation against 15O-H2O PET. Alzheimers Dement. 2019;15:1172–1182. 16. Ottoy J, Verhaeghe J, Niemantsverdriet E, Engelborghs S, Stroobants S, Staelens S. A simulation study on the impact of the blood flow-dependent component in [18F] AV45 SUVR in Alzheimer’s disease. PLoS One. 2017;12:e0189155. 3
RkJQdWJsaXNoZXIy MjY0ODMw